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Background: Due to their restricted expression in male germ cells and certain tumors, cancer/testis (CT) antigens
are regarded as promising targets for tumor therapy. CT45 is a recently identified nuclear CT antigen that was
associated with a severe disease score in Hodgkin’s lymphoma and poor prognosis in multiple myeloma. As for
many CT antigens, the biological function of CT45 in developing germ cells and in tumor cells is largely unknown.
Methods: CT45 expression was down-regulated in CT45-positive Hodgkin’s lymphoma (L428), fibrosarcoma
(HT1080) and myeloma (U266B1) cells using RNA interference. An efficient CT45 knock-down was confirmed by
immunofluorescence staining and/or Western blotting. These cellular systems allowed us to analyze the impact of
CT45 down-regulation on proliferation, cell cycle progression, morphology, adhesion, migration and invasive
capacity of tumor cells.
Results: Reduced levels of CT45 did not coincide with changes in cell cycle progression or proliferation. However,
we observed alterations in cell adherence, morphology and migration/invasion after CT45 down-regulation.
Significant changes in the distribution of cytoskeleton-associated proteins were detected by confocal imaging.
Changes in cell adherence were recorded in real-time using the xCelligence system with control and siRNA-treated
cells. Altered migratory and invasive capacity of CT45 siRNA-treated cells were visualized in 3D migration and
invasion assays. Moreover, we found that CT45 down-regulation altered the level of the heterogeneous nuclear
ribonucleoprotein syncrip (hnRNP-Q1) which is known to be involved in the control of focal adhesion formation
and cell motility.
Conclusions: Providing first evidence of a cell biological function of CT45, we suggest that this cancer/testis
antigen is involved in the modulation of cell morphology, cell adherence and cell motility. Enhanced motility and/
or invasiveness of CT45-positive cells could contribute to the more severe disease progression that is correlated to
CT45-positivity in several malignancies.Background
Cancer/Testis (CT) antigens comprise a heterogeneous
group of now more than 150 proteins with an eponymous
expression pattern being restricted to male germ cells in
normal human testis and to tumor cells of different origin
[1-3]. CT antigens encoded on the X-chromosome form
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reproduction in any medium, provided the orantigens induce specific cellular or humoral immune re-
sponses, they are regarded as promising targets for anti-
tumor immunotherapy due to their absence from normal
tissues [1,4,5]. In fact, fusion proteins or peptides derived
from some of the first identified CT antigens such as
MAGE-A3 and NY-ESO-1 are subject of present clinical
phase II and III studies to evaluate their potential as can-
cer vaccines, e.g. for the treatment of myeloma [6-9]. Sur-
prisingly, and also true for the CT antigens that were
discovered already some 20 years ago, almost nothing is
known about their function in developing germ cells or
CT antigen-positive tumor cells [1,2].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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signature sequencing and comprises 6 highly similar
genes which are located on the X-chromosome (Xq26.3)
[10]. CT45 is a nuclear protein with significant similarity
to the CT-X antigen SAGE (CT14) and the D-E-A-D
box containing protein DDX26 [10]. In normal human
tissues, CT45 expression is restricted to spermatogonia
and spermatocytes. Many human tumors do not express
CT45 at all. In some tumors, e.g. colon carcinoma,
CT45 is expressed in a low number of cases (10%). Only
in germ cell tumors (e.g. seminoma), in Hodgkin’s
lymphoma, ovarian cancer and multiple myeloma, CT45
is expressed in a larger number of cases [11-15]. Similar
to other CT antigens, CT45 gene expression is epigeneti-
cally controlled by methylation [6,16,17]. Thus, methylated
CpG islands in the CT45 promotor suppress CT45 expres-
sion, whereas demethylation by 5′-aza-2′-deoxycytidine
treatment induces the expression of CT45 even in a priori
CT45-negative HeLa cells [12] (and own unpublished
results).
At the protein level, CT45 migrates as a double band
of 22/25 kDa after immunopurification and/or Western
blotting [12]. Initial immunocytochemical analyses using
the anti-CT45 mab Ki-A10 revealed that CT45 is exclu-
sively found in the nuclei, with a strong enrichment in
so-called nuclear speckles [18]. Evaluation of a large
panel of Hodgkin‘s lymphoma with this monoclonal
antibody facilitated the discrimination of Hodgkin's
lymphoma from lymphadenopathies. Moreover, a high
expression of CT45 correlated with more aggressive
histological subtypes, B symptoms (e.g. fever, night
sweats, and weight loss) and advanced stages, indicating
that CT45 might serve as a marker for a worse course of
Hodgkin’s lymphoma [19,20]. Similarly, in a recent inde-
pendent study, poorer prognosis and outcome were also
demonstrated for multiple myeloma patients with CT45-
positive tumors as compared to CT45-negative specimen
[13].
Thus, CT45 has already proven its relevance as a po-
tential prognostic marker for several types of tumors
[13,19,20]. Its association with disease progression, se-
verity and poor prognosis suggests that CT45 might
somehow support tumor cell malignancy or aggressive-
ness, as has been proposed for other CT antigens. For
instance, altered cell proliferation and/or motility were
observed upon down-regulation of members of the
MAGE-family in mast cells or multiple myeloma cells
and SSX in mesenchymal stem cells or by ectopic
overexpression of CAGE in fibroblasts [21-24].
In order to assess the cell biological function of CT45,
we investigated the effects of CT45 down-regulation by
RNA interference in established CT45-positive Hodgkin’s
lymphoma, myeloma and fibrosarcoma cell lines. We
report that reduced levels of CT45 do not alter cellcycle progression or proliferation, but modulate cell
morphology, adherence and migration as shown for
Hodgkin’s lymphoma and/or fibrosarcoma cell lines. We
suggest that altered cell morphology, enhanced motility
and invasiveness of CT45-positive cells might contribute
to the higher degree of malignancy that has been asso-
ciated with CT-positive Hodgkin’s lymphoma and mul-
tiple myeloma.
Results
Subcellular localization of CT45 and down-regulation of
CT45 by RNA interference
CT45-positive Hodgkin’s lymphoma (L428), fibrosarcoma
(HT1080) and myeloma (U266B1) cells were examined by
immunofluorescence staining with the CT45-specific mab
Ki-A10. We observed a dot-like nuclear expression of
CT45 in the suspension cell lines L428 (Figure 1A) and
U266B1 (Additional file 1: Figure S1A) and also in adher-
ently growing HT1080 cells (Figure 1B). Immunofluores-
cence staining of L428 or HT1080 cells transfected with
either scrRNA or CT45-specific siRNA was performed
using mab Ki-A10 72 h after transfection. SiRNA-treated
L428 or HT1080 cells showed an almost complete
down-regulation of CT45 protein (Figure 1A, B). Down-
regulation of CT45 by specific RNA interference resulted
in a clear reduction of CT45 protein levels in the
tested cell lines between 24 h to 96 h after transfec-
tion (Figure 1C, D, supplemental Figure 1B). Cell lysates
of scrRNA- or siRNA-treated cells were prepared 24 to
144 h after transfection and analyzed by Western blotting.
The predominant nuclear distribution was verified by
probing cytoplasmic and nuclear extracts of L428 and
HT1080 cells. CT45 was detected in the nuclear fraction
but not in the cytoplasm (Figure 1C, D) where GAPDH
served as a marker for the cytosolic and nucleolin for the
nuclear fraction. Of note, for detecting CT45 from L428
cells, we used mab Ki-A10 and from HT1080 cells mab
Ki-CT45-2. Although CT45 was detected in HT1080 cells
by immunofluorescence staining using mab Ki-A10, it was
barely visible in lysates of HT1080 cells using this anti-
body, presumably due to a significantly lower overall
protein abundance as was indicated by the immunofluor-
escence staining. Interestingly, however, the newly
established anti-CT45 antibody Ki-CT45-2 that is di-
rected against an N-terminal epitope of CT45 (data not
shown) also stained the protein in HT1080 lysates.
Down-regulation of CT45 does not interfere with
proliferation
To assess whether the knock-down of CT45 would influ-
ence the autonomous proliferation of L428, HT1080 or
U266B1 cells, we performed BrdU incorporation assays
to analyze DNA synthesis (Figure 2A, B, supplemental
Figure 1C) and MTS assays to measure metabolic
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Figure 1 Subcellular localization of CT45 and down-regulation of CT45 by RNA interference. Immunofluorescence staining of cytospin
preparations of L428 cells (A) and of adherently growing HT1080 cells (B) treated with scrambled (scrRNA) or with CT45-specific (CT45 siRNA)
with mab Ki-A10. DAPI was used for DNA staining. Down-regulation of CT45 using CT45 siRNA was analyzed after 72 h (A, B) or over a period of
up to 144 h in L428 (C) and HT1080 cells (D). Cytoplasmic and nuclear fractions of the cells were prepared and CT45 expression was analyzed
with mab Ki-A10 in L428 and mab Ki-CT45-2 in HT1080 cells. β-actin staining was performed to demonstrate equal loading, GAPDH was used as a
cytoplasmic and nucleolin as a nuclear marker. All experiments were performed at least three times. White bars indicate 20 μm.
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reported for several other CT antigens, the specific down-
regulation of CT45 did not have any apparent effect on
the proliferation of the tested tumor cells. No significant
differences between control cells and siRNA-treated cells
were observed at any time point. Furthermore, siRNA-
and scrRNA-treated L428 (Figure 3A), HT1080 (Figure 3B)
and U266B1 (supplemental Figure 1D) cells were collected
at different time-points and subjected to cell cycle analysis
by flow cytometry using the DNA dye propidium iodide.
One representative experiment performed 72 h after
transfection is shown for each cell line. As calculated from
the individual FACS profiles shown in the upper panels,
there was no detectable effect on the distribution of cells
in the different phases of the cell cycle (Figure 3A, B, sup-
plemental Figure 1D, lower panels).
CT45 knock-down alters morphology
On the basis of our observation that siRNA-treated
HT1080 cells were less adherent on FCS-coated glass
slides compared to control cells, we analyzed the intracel-
lular distribution of characteristic cytoskeletal elements.
Since morphological changes were best seen in HT1080cells, we performed the next series of experiments with
the adherently growing fibrosarcoma cell line. ScrRNA-
and siRNA-treated HT1080 cells were stained 72 h after
transfection with antibodies specific for actin, microtubules
and intermediate filaments (Figure 4A), or specific for
marker proteins for focal adhesion proteins (Figure 4B).
Double immunofluorescence staining of scrRNA-treated
control cells with Ki-A10 and antibodies specific for actin, ß-
tubulin and vimentin reflected the normal morphology of
adherently growing HT1080 cells. In contrast, CT45 down-
regulated cells revealed an altered morphology as indicated
by changes in the cell shape (e.g. upper panels, ß-actin stain-
ing) and the organization of the microtubule network (mid-
dle panels, ß-tubulin staining) which appeared more diffuse
and unorganized in siRNA-treated cells. Similar to actin, also
the staining for vimentin, a marker protein of intermediate
filaments, pointed to major alterations in cell shape and size.
Moreover, the comparison of scrRNA- and siRNA-treated
cells using antibodies specific for phosphorylated focal adhe-
sion kinase (FAK Y397) and parvin alpha - both proteins
play an important role in the regulation of cell adherence -
showed a markedly reduced number of active focal adhe-
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Figure 2 Impact of CT45 down-regulation on cell proliferation. BrdU (A, B) and MTS (C, D) assays were performed in quadruplicates to
determine the effect of CT45 down-regulation on cell metabolism and proliferation of L428 (A, C) and HT1080 (B, D) cells. Data are shown for
representative experiments of two to six independent assays. In all cases, inhibition of CT45 expression had no significant effect on cell
proliferation and cell growth in the tested cell lines.
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Having shown that the cytoskeletal composition and the
formation of cell contacts were altered in the presence
of CT45, we next analyzed its potential impact on cell
adherence and motility. First, a real-time analysis of cell
adherence was performed using the xCelligence system
from Roche. With this assay system, we recorded alter-
ations of the cellular impedance of in vitro cultured
scrRNA- and siRNA-treated HT1080 cells over time
(Figure 5A). As expected, the transfected cells displayed
a slightly decreased cell index as compared to un-
transfected cells. During the first 34 h after transfection,
no difference in the cellular impedance was seen between
scrRNA- and CT45 siRNA-treated cells (Figure 5B). After
34 h, however, the cellular impedance of siRNA-treated
cells decreased, reaching a maximal difference at 68–72 h
after transfection (Figure 5C). To ensure that the observed
effects on cellular impedance were not due to changes in
proliferation, both cell populations were labeled with
BrdU 34 h after transfection. As expected, we did not de-
tect alterations in the proliferative capacity in the presence
or absence of CT45 (data not shown). Since cellular im-
pedance in this system is influenced by the number of
cells and their individual adherence, we concluded that
CT45 down-regulation reduced the adherence of siRNA-
treated HT1080 cells.We next tested the migratory and invasive capacity of
scrRNA- and CT45 siRNA-treated HT1080 cells using
transwell migration and invasion assay systems. All ana-
lyses were performed 48 h after down-regulation of
CT45 using cytochalasin D-treated HT1080 cells as an
internal control. The cells were placed in the upper
chamber of the transwell system and incubated for 4 h
before staining and quantification. The data analysis re-
vealed that cell migration of siRNA-treated HT1080 cells
was down-regulated by 23% (Figure 6A, D). In addition,
staining of cells collected from the lower chamber revealed
that less siRNA-transfected and only very few cytochalasin
D-treated cells had passed the membrane. A subsequent
analysis of HT1080 cells in a modified cell invasion assay
confirmed the previous results (Figure 6B, E). Moreover,
also the cell migration of the non-adherent CT45-
positive Hodgkin’s lymphoma cells L428 was significantly
reduced upon siRNA-treatment in a separate migration
assay (Figure 6C).
Potential impact of CT45-regulated syncrip on cell
morphology
2D-DIGE experiments comparing scrRNA- and CT45
siRNA-treated cells revealed that syncrip (hnRNP-Q), a
mRNA-binding heterogeneous nuclear ribonucleopro-
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Figure 3 Impact of down-regulation of CT45 on cell cycle progression. 72 h after transfection with scrRNA or CT45 siRNA, cells were
harvested and labeled with propidium iodide. The analysis of the different cell cycle phases of L428 (A) and HT1080 (B) cells was performed by
flow cytometry. Representative histograms for scrRNA- or CT45 siRNA-treated cells are shown in the upper and middle panels. A quantification
using the indicated regions is depicted in the lower panels. Down-regulation of CT45 had no apparent impact on cell cycle progression. All
experiments were performed at least three times.
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Figure 4 Down-regulation of CT45 alters cell morphology. (A) 72 h after transfection, double immunofluorescence staining of adherently
growing HT1080 cells with mab Ki-A10 and antibodies specific for actin, ß-tubulin and vimentin was performed. ScrRNA-treated cells demonstrate
normal cell morphology, whereas CT45 siRNA-treated cells show a significantly altered cell morphology (right panels in A). (B) Double
immunofluorescence staining of focal adhesion proteins FAK Y397 and parvin alpha was performed in HT1080 cells 72 h after siRNA transfection.
Focal adhesion sites in scrRNA-treated cells are indicated by arrows. Down-regulation of CT45 resulted in a markedly reduced number of FAK
Y397- and parvin α-positive focal adhesion sites. White bars indicate 20 μm.
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Figure 5 Influence of CT45 down-regulation on the time-dependent adherence profiles of HT1080 cells. (A) To analyze the effect of
down-regulation of CT45 on cell adhesion, we performed real-time measurements of the cell impedance over a period of 108 h with HT1080
cells as a control (red line), scrRNA-transfected cells (green line) and CT45 siRNA-transfected cells (blue line). Starting after 34 h, the cellular
impedance of CT45 siRNA-treated cells decreased significantly reaching a maximal difference (18%) at 68–72 h after transfection. The changes in
the cell indices were calculated for the time intervals 0–34 h (B) and 0–68 h (C), respectively using the RTCA-integrated software provided by the
manufacturer. Data of one representative experiment (with four individual biological replicates) of four are shown.
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after CT45 siRNA transfection of HT1080 and L428
cells (unpublished data, PhD thesis of Anja Koop, CAU,
Kiel). Western blot analyses of lysates of HT1080 and
L428 cells obtained 72 h after CT45 siRNA transfection
confirmed these results (Figure 7A). Along with the
down-regulation of CT45 (demonstrated by staining
with mabs Ki-A10 and Ki-CT45-2, respectively), also
syncrip was reduced in siRNA-treated cells. Immuno-
fluorescence staining of HT1080 cells with an hnRNP-Q-
specific mab showed a weak dot-like nuclear expression
and a strong cytoplasmic staining in scrRNA-treated
cells (Figure 7B, left panel). In contrast, in CT45 siRNA-
treated cells using the same settings, the cytoplasmic
staining was much less prominent suggesting that CT45
somehow regulates the subcellular distribution of syncrip
(Figure 7B, right panel).
Regarding the regulatory function of syncrip on mor-
phogenesis, recent reports suggest that syncrip might
interact with several mRNAs encoding for key proteins
of cytoskeletal reorganization including RhoA, Cdc42,
N-WASP and constituents of the Arp complex [26,27].
In neurons, the absence of syncrip results in an inappro-
priate localization of these proteins and in abnormal
neurite arborization and morphological alterations. Wetherefore analyzed whether syncrip would also bind to
respective mRNAs of CT45-positive tumor cells and
whether the knock-down of CT45 would alter the
amount of precipitated mRNA. To this end, we per-
formed mRNA-co-immunoprecipitations from L428
cells (Figure 8). We detected equal levels of individual
mRNAs in the lysates of scrRNA- and CT45 siRNA-
treated cells. However, when we precipitated syncrip
from these lysates, in correlation to the reduced level of
syncrip, we also observed a reduction of co-precipitated
mRNA for Cdc42, N-WASP, Arp2 and Arp3. With these
initial hints, we suggest that also in the investigated
tumor cells, the reduction of CT45 alters the syncrip-
driven regulation of cytoskeletal elements.
Discussion
To assess the relevance of CT45 in tumor cells, we ana-
lyzed L428 (Hodgkin’s lymphoma), U266B1 (myeloma/
plasmacytoma) and HT1080 (fibrosarcoma) cells. Al-
though these cell lines differ in their origin and morph-
ology, e.g. HT1080 cells being adherent and L428 and
U266B1 cells non-adherent, they were used because they
homogenously express CT45. In all three cell types, a
strong nuclear expression of CT45 was detected with a
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Figure 6 CT45 affects cell invasion and migration. (A-C) Cell migration and cell invasion capacities of scrRNA- or CT45 siRNA-treated HT1080
or L428 cells were analyzed in colorimetric or fluorometric transwell systems as described in the experimental procedures (A, D: HT1080
migration, B, E: HT1080 invasion, C: L428 migration). As a control, cell motility was inhibited with 2 μM Cytochalasin D. The data analysis revealed
that cell migration of siRNA-treated HT1080 cells was down-regulated by 23%. Staining of cells collected from the lower chamber revealed that
less siRNA-transfected and only very few cytochalasin D-treated cells had passed the membrane (D). The cell invasion assay of HT1080 (B, E) and
the migration assay for L428 cells (C) revealed similar results. All experiments were performed at least three times.
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are dynamic structures that form storage sites of pre-
mRNA splicing factors [28]. Although off-target effects
are more and more discussed, the inhibition or down-
regulation of proteins by RNA interference has proven
to be an excellent tool to obtain unbiased information
about the function of otherwise poorly characterized
proteins in many instances, also including studies on CT
antigens [21,22,29]. Using CT45-specific siRNA, a sub-
stantial down-regulation of CT45 was visible 24 h after
transfection of HT1080, U266B1 and L428 cells with an
almost complete knock-down after 72 to 96 h. Down-
regulation was transient, since 144 h after transfection,
CT45 expression was again detectable.
Altered proliferation, cell morphology, adherence, mi-
gration and invasion are typical characteristics of cancer-
ous cells [24,30]. It was shown before that higher levels
of the cancer/testis antigens CT7 and MAGE-A3/6 cor-
related with increased plasma cell proliferation [23], and
that down-regulation of members of MAGE-A, -B, and -C
families by siRNA reduced cell proliferation of human
HMC1 and murine P815 mast cells. In addition, these two
cell lines displayed a prolonged S-phase 24 h after siRNAtransfection [21]. Moreover, Por and coworkers described
that the down-regulation of the cancer/testis antigen
CAGE by RNA interference retarded cell proliferation in
HeLa and Malme-3 M melanoma cells [22]. Therefore, we
initially analyzed the effects of CT45 down-regulation on
the proliferation of L428, HT1080 and U266B1 cells.
However, although we used different approaches to assess
cell proliferation, we did not observe any alterations in cell
growth upon CT45 knock-down. In addition, we also did
not detect any impact on cell-cycle progression through-
out the observation time of up to seven days.
In the course of our studies, however, we noted appar-
ent differences in cell adherence and morphology upon
siRNA-treatment of adherent HT1080 cells. Changes in
the intracellular distribution of key cytoskeletal elements
were demonstrated by immunofluorescence staining for
actin, ß-tubulin and vimentin. Here, scrRNA-treated
cells showed a characteristic morphology with needle-
like filopodia. In contrast, in siRNA-treated cells, filo-
podia formation seemed to be impaired. The analysis of
marker proteins for cell adherence such as the focal adhe-
sion kinase (FAK) revealed several focal adhesion sites on





   
































Figure 7 CT45 influences the expression of syncrip. (A) L428 and
HT1080 cells were transfected with scrRNA or CT45 siRNA,
respectively. 72 h after transfection, Western blot analyses of cell
lysates were performed using antibodies specific for CT45 (Ki-A10 for
L428 cells, and Ki-CT45-2 for HT1080 cells), syncrip and ß-actin (as
loading control). 72 h after down-regulation of CT45, syncrip is also
down-regulated in both cell lines. (B) In parallel, immunofluorescence
staining for syncrip of scrRNA-transfected and CT45 siRNA-transfected
HT1080 cells was performed. DAPI was used for visualization of the
























































Figure 8 Syncrip selectively co-precipitates mRNAs of Cdc42,
N-WASP, Arp2, Arp3 but not GAPDH and CT45. L428 cells were
transfected with scrRNA or CT45 siRNA, respectively. 72 h after
transfection, cell lysates were prepared and syncrip
immunoprecipitations performed as detailed in Material and
Methods. Protein A beads used for preclearing were used as internal
control (co) for the RT-PCR or Western blot. In addition, respective
RT-PCRs were also performed using unseparated cell lysates as
starting material. The whole cell lysates were also used to document
the mild reduction of syncrip protein by Western blotting (WB,
upper panel for syncrip, short exposure; lower panel, long exposure).
The RT-PCR revealed that mRNAs for Cdc42, N-WASP, Arp2 and Arp3
(but not CT45 or GAPDH) could be amplified from syncrip-
immunoprecpitations. In addition, the amount of co-precipitated
mRNA was reduced in CT45 siRNA-treated cells.
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that overexpression of the cancer/testis antigen CAGE
enhanced the cell motility of cancer cells [31]. Phosphor-
ylated FAK was significantly overexpressed in CAGE-
expressing cells. Thus, our immunofluorescence analyses
pointed to a first potential function of CT45 in the regu-
lation of cell adhesion and migration.
It is evident that cell migration plays a pivotal role in a
wide variety of biological processes including embryo-
genesis and cancerogenesis or metastasis formation [32].
Recently, Cronwright and colleagues demonstrated that
down-regulation of the CT antigen SSX affected cell mi-
gration of a melanoma cell line, indicating that also SSX
might support cell migration of certain tumor cells [24].
Along this line, the cell migration and invasion assays
that we performed with HT1080 and L428 cells clearly
indicated that CT45 is involved in the regulation of both
cell migration and invasiveness. Since enhanced migra-
tion and invasion may contribute to an increased meta-
static potential of CT45-expressing cells, this might inpart explain the more severe disease progression and
poorer prognosis in patients with CT45-positive tumors.
It is noteworthy in this context that also tumor-associated
non-CT antigens such as for example the neuronal trans-
membrane cell adhesion molecule L1CAM (CD171) have
a strong impact on cell migration and invasion when “re-
expressed” in treatment-resistant forms of ovarian and
pancreatic cancer (while being absent from normal tis-
sues) [33]. Even more interesting, the localization of the
L1 gene on the X-chromosome (Xq28) and also its (de-)
regulation by hypomethylation, very much resembles what
has been observed for several CTX, including CT45. Since
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range epigenetic remodelling as a mechanism for regional
activation of a cancer genome [34], this might in part ex-
plain the new appearance of ‘mislocated’ protein products
from otherwise silenced genes.
The obtained information, however, provokes the
question of how nuclear CT45 could alter cell adherence,
morphology and invasiveness. Here, we demonstrate that
the CT45 knock-down coincides with a down-regulation
and altered distribution of the ribonuclear protein syncrip
(hnRNP-Q). Until now, three functionally active isoforms
of syncrip are known (hnRNP-Q, -Q2 and -Q3) [25]. Ap-
parently, two of these isoforms are predominantly located
in the nucleus and are required for efficient pre-mRNA
splicing whereas the third isoform is mostly found in the
cytoplasm. Xing and colleagues recently reported that
down-regulation of hnRNP-Q induced an up-regulation
of the small GTPase RhoA causing morphological changes
in murine C2C12 myoblastoma cells [26]. Furthermore, a
reduction of syncrip induced evident morphological
changes in rat cortical neurons and mouse neuroblastoma
cells by regulating actin dynamics via the Cdc42/N-
WASP/Arp2/3-pathway [27]. Therefore, it was concluded
that syncrip is involved in mRNA processing to regulate
transcription of cytoskeleton-regulatory proteins. Thus,
being localized in a common nuclear compartment,
syncrip could form the functional link between CT45 and
the observed alterations in cell morphology and migration
observed in our study. To support this hypothesis, the
mRNA co-precipitation with syncrip revealed reduced
levels of Cdc42, N-WASP, Arp2 and Arp3 mRNAs from
CT45 siRNA-treated L428 cells. In line with the report by
Xing and colleagues for neurons, in preliminary experi-
ments, we observed a mild increase in RhoA when syncrip
was reduced due to the CT45 knock-down. Moreover, we
noted a slightly increased phosphorylation of cofilin argu-
ing that changes might also occur at the level of
postranslational modification of individual cytoskeletal
proteins (data not shown). However, more extensive stud-
ies are needed to address how the changes in mRNA
levels are eventually translated into the observed morpho-
logical changes. It will be important to analyze cytoskel-
etal or motility-promoting protein complexes in the
presence or absence of CT45 and/or syncrip and to ad-
dress changes in the subcellular localization or post-
translational modifications.
Conclusion
We provide first experimental evidence for a cell bio-
logical function of the cancer/testis antigen 45. We dem-
onstrate that CT45 is involved in the regulation of cell
morphology, adherence and migration. Enhanced motil-
ity and/or invasiveness of CT45-positive cells could be
advantageous for spreading or metastasis formation andthereby contribute to the higher degree of malignancy or




The cell lines L428 (Hodgkin’s lymphoma, catalogue code
ACC-197, German Collection of Microorganisms and Cell
Cultures (DSMZ) Braunschweig, Germany), U266B1
([U266] myeloma/plasmacytoma, ATCC® TIB-196™) and
HT1080 (fibrosarcoma, catalogue code ACC-315, DMSZ)
were grown in RPMI 1640 or DMEM, respectively. Media
were supplemented with 10% fetal calf serum, 10 mM glu-
tamine, 25 mM HEPES and 50 μg/ml streptomycin and
penicillin.
Immunofluorescence microscopy
For immunofluorescence staining, cytospin preparations
of L428, U266B1 or HT1080 cells growing on fetal calf
serum (FCS)-coated glass slides were fixed for 10 minutes
in ice-cold methanol. The CT45-specific mab Ki-A10
was used for immunofluorescence staining [11,12]. Anti-
bodies specific for syncrip (hnRNP-Q), actin and parvin
alpha were purchased from Abcam (Cambridge, UK), for
vimentin and focal adhesion kinase phosphorylated on
tyrosine 397 (FAK Y397) from Cell Signaling Technology
(Danvers, MA, USA) and for ß-tubulin from Sigma-
Aldrich (Munich, Germany). Unlabeled mab were stained
with donkey anti-mouse Alexa 488 or donkey anti-rabbit
Alexa 594 (Invitrogen, Karlsruhe, Germany). DNA stain-
ing was performed with DAPI (Invitrogen). Confocal laser
scanning microscopy was performed using an LSM 510
Meta microscope (Carl Zeiss, Jena, Germany).
Silencing of CT45 in HT1080, U266B1 and L428 cells by
RNA interference
Out of six different siRNAs that were initially tested,
only one siRNA sequence (sense 5′-3′ GGAGAGAAAA
GGAUCAGAUUU) was able to target the CT45 tran-
script effectively. For control purposes, a scrambled se-
quence was generated and verified (scrRNA 5-3′CUCG
ACAUAACACUGGUGCUU). The RNAs were pur-
chased from Ambion/Applied Biosystems (Austin, TX,
USA) and used at a concentration of 100 nM. Transfection
was performed by electroporation using Nucleofector™ II
equipment and nucleofector Kits for L428 and U266B1
(Kit L) and HT1080 cells (Kit T; Lonza, Cologne,
Germany).
Western blot analysis
After intense washing with ice-cold PBS, cells were lysed
with 2% Triton-X 100, 1 mM EDTA and a protease in-
hibitor cocktail (Roche, Mannheim, Germany) in PBS
for 2 minutes. Enriched cell nuclei were pelleted and
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enriched nuclear lysate was centrifuged at 15.000 × g.
The resulting supernatant was boiled in loading buffer
under reducing conditions and separated by SDS-PAGE.
Immunostaining of blotted proteins was performed as
described [35]. For some experiments, the ProteoJET™
Cytoplasmic and Nuclear Extraction Kit (Fermentas, St.
Leon-Rot, Germany) was used following the manufac-
turer’s protocol.
Cell proliferation and metabolic activity
Metabolic activity / proliferation of HT1080, U266B1
and L428 cells was measured by two colorimetric immu-
noassays according to the manufacturer’s protocols
(BrdU-Assay Kit; Roche, Mannheim, Germany; MTS
assay, Promega, Mannheim, Germany). HT1080 cells
were seeded at a density of 5×103 cells/well, L428 and
U266B1 at a density of 2×104 cells/well into 96-well flat
bottom tissue culture plates. The total incubation period
after transfection was 72 h (MTS) or 96 h (BrdU) and
the metabolic activity or cell proliferation was measured
every 24 h. For quantification, a microplate spectropho-
tometer was used with a detection wavelength of
490 nm for the MTS assay and detection at 490 nm with
reference to 405 nm for the BrdU assay.
Cell cycle analysis
ScrRNA- and siRNA-treated L428, U266B1 and HT1080
cells were washed with PBS and fixed in 50% ethanol at
4°C. After 30 min of fixation, the cells were washed twice
in PBS, suspended in 0.1 ml PBS containing 40 μg/ml
RNase A and incubated for 30 min at room temperature
before 0.5 ml staining solution (50 μg/ml propidium iod-
ide in PBS/5 mM EDTA) was added. Cell cycle analysis
was performed by flow cytometry using a FACSCalibur
Analyzer (Becton Dickinson).
Real-time monitoring of HT1080 cells using the
xCELLigence system
The xCELLigence system (Roche Applied Science,
Mannheim, Germany) monitors cellular events in real-
time by recording the electrical impedance that is corre-
lated with cell number, morphology and viability in a







CT45 ATGACCGATAAAACAGAGAAGGCT45 knock-down, we used 96 well microtiter E-plates.
Fifty μl of culture medium were applied to determine the
background impedance (30 min). Then, untransfected,
and individually scrRNA- or CT45 siRNA-transfected
HT1080 cells were adjusted to 200.000 cells/ml and 50 μl
of each cell suspension was pipetted to three or four wells
of the E-plate before placing it into the RTCA SP Station.
Cell impedance was monitored every five minutes for the
first hour and every ten minutes for the next 108 hours.
The electrical impedance was calculated by the RTCA-
integrated software of the xCELLigence system as a di-
mensionless parameter termed CI. Median values and
standard deviations were calculated from four (in some
experiments three) individual wells reflecting four (three)
individual controls, scrRNA- or CT45 siRNA-transfections.
The changes in cell indices for the time intervals 0–34 h
and 0–68 h were also calculated by the RTCA-integrated
software.
Transwell invasion and migration assays
To determine the migratory and invasive potential of
HT1080 cells after CT45 knock-down, we used the
CytoSelect™ 24-well cell migration and invasion assay,
colorimetric format (8 μm-pore size, CBA-100-C) from
Cell Biolabs Inc. (San Diego, USA). In addition, cell mi-
gration of L428 cells was analyzed with the CytoSelect™
24-well cell migration assay, fluorometric format (5 μm-
pore size, Cat. CBA-102). The assays were performed as
described in the manufacturer´s protocol. In brief, cells
were washed once in serum free medium and seeded
into the upper chamber onto a rehydrated basal layer
membrane covering a matrigel preparation with a diam-
eter of 8 μm (HT1080 cells) or 5 μm (L428 cells), re-
spectively. For negative controls, 2 μM cytochalasin D
was added. To investigate the invasive potential of
scrRNA- and CT45 siRNA-transfected HT1080 cells, the
cells were allowed to invade for 24 h. The migration cap-
ability of HT1080 cells was analyzed after 4 h and of
L428 cells after 6 h of incubation. HT1080 cells on the
bottom of the membrane were stained according to the
manufacturer’s protocol, visualized with a light micro-
scope and quantified as described in the assay protocol.
L428 cells were removed from the lower surface of the
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structions. All assays were repeated at least three times.mRNA-immunoprecipitation
For mRNA-immunprecipitation, 107 L428 cells were
lysed in 1 ml RSB100-buffer (10 mM Tris pH 7.4,
100 mM NaCl, 2.5 mM MgCl2) with 0.5 mg/ml digitonin
for 20 minutes at 4°C. Lysates were centrifuged for
5 min at 1500 × g and the supernatant was further
centrifuged for 15 min at 4000 × g. The resulting super-
natant was then pre-cleared with 100 μl RSB100-buffer
/protein-A-sepharose beads (50% (v/v), these beads were
washed and used as controls). For mRNA-IP, the sam-
ples were incubated with 5 μg anti-syncrip antibody
(Abcam) and protein-A-sepharose beads in RSB100-
buffer for 2 hours. Pelleted beads were washed thrice
with NET-2 buffer (50 mM Tris pH 7.4, 150 mM NaCl)
with 0,5% Triton X-100. Finally, an equal volume of
RSB100-buffer was added to the protein-A-sepharose
and the samples were divided into two aliquots for
mRNA isolation, cDNA synthesis and PCR or Western
blotting, respectively. As a positive control, mRNA was
also isolated from whole cell lysates. For mRNA isola-
tion, the RNeasy Kit from Qiagen (Hilden, Germany)
was used and for cDNA synthesis, the First Strand
cDNA Synthesis Kit from Fermentas according to the
manufacture's instructions. Cdc42, N-WASP, Arp2,
Arp3, GAPDH and CT45 sequences were amplified from
2 μg cDNA using Dream Taq™ Polymerase (5 U/μl,
Fermentas) and the primer pairs listed in Table 1. Frag-
ments were analyzed on agarose-gel (1%) with ethidium
bromide.Additional file
Additional file 1: Figure S1. Subcellular localization of CT45 and down-
regulation of CT45 by RNA interference in U266B1 myeloma cells.
(A) Immunofluorescence staining of cytospin preparations of U266B1
cells with mab Ki-A10. DAPI was used for DNA staining. (B) Down-
regulation of CT45 using CT45 siRNA was analyzed by Western blotting in
whole cell lysates 24, 48, 72, 96 and 144 hours after transfection. (C) A
BrdU incorporation assay was done to determine the effect of CT45-
down-regulation on the proliferation of U266B1 cells. (D) Cell cycle
analyses were performed by flow cytometry 72 h after transfection with
scrRNA or CT45 siRNA using propidium iodide. Histograms for scrRNA- or
CT45 siRNA-treated cells are shown in the upper panels. A quantification
using the indicated regions is depicted in the lower panel. Down-
regulation of CT45 had no apparent impact on proliferation or cell cycle
progression of U266B1 myeloma cells.Competing interests
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